Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Surgical Science in conjunction with a directed new issue of shares valued at SEK 2.7 billion
Mandate

Vinge advises Surgical Science in conjunction with a directed new issue of shares valued at SEK 2.7 billion

July 29, 2021 Capital Markets and Public M&A

Surgical Science Sweden AB, listed on Nasdaq First North Growth Market, has performed a directed new issue of shares valued at approximately SEK 2.7 billion at a subscription price of SEK 210.

The subscription price was established through a so-called accelerated book building procedure arranged by Pareto Securities. The net proceeds from the directed issue of shares will primarily be used to finance the acquisition of Simbionix USA Corp which was made public on the same day as the directed new issue of shares. 

Vinge’s team consisted of Anders Strid, Edin Agic (project manager) and Adrian Filipovic.

 

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026